The Hemostats market size in the Asia Pacific is valued at around USD 680 million in 2020. It is expected to grow at a CAGR of 6.9% to reach USD 940 million by 2025. The Asia Pacific is set on a high growth trajectory in the forecast above period. The booming medical tourism industry, rising disposable income resulting in higher purchasing power, and rising awareness regarding better health infrastructure are the reasons behind this. It captures 20% of the global market.
Y-O-Y growth in the aging population in Asia Pacific countries such as Indian and China, a growing number of surgical procedures, and trauma cases are estimated to drive the market growth in this region. Additionally, an increasing number of FDA approval processes, rising medical tourism industry, enhancing medical healthcare infrastructure are expected to favor the market growth of hemostats in the Asia Pacific. Growing discretionary expenses, increasing investments for healthcare, and reimbursement scenarios are contributing support to the market.
Rigorous regulatory procedures, less awareness regarding the benefits associated with the hemostat products, and high cost of hemostat equipment and treatment are majorly restraining the market growth in the Asia Pacific. Rules and regulations made of APAC governments and experienced professionals' needs are significant challenges hindering the development.
This research report on the APAC Hemostats Market has been segmented and sub-segmented into the following categories:
Regionally, the hemostats market in Asia-Pacific is the fastest-growing region globally due to the patient population with significant growth in surgical procedures and growing product launches.
The Chinese market is expected to dominate the Asia Pacific market during the forecast period. The increasing number of sports-related injuries, advanced technologies, and rising attention towards the effective blood loss management in patients at the time of surgeries are expected to drive the market.
Indian hemostats market is anticipated to have witnessed rapid growth during the review period. The number of hospitals rose from 35,416 to 37,725 from 2017-15; according to the Ministry of Health and Family Welfare, Government of India, healthcare amenities, the increased amount spent towards healthcare fuels the market during the historical period.
The Top companies leading in the APAC Hemostats Market profiled in the report are 3M, ADCO Asia Pacific, Inc., Abbott Laboratories. Other players in the market include Advanced Medical Solutions Group, Plc. And Dymax Corporation.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product Type
5.1.1 Introduction
5.1.2 Topical hemostats
5.1.2.1 Collagen-based topical hemostats
5.1.2.2 Oxidized regenerated cellulose-based topical hemostat
5.1.2.3 Gelatin-based topical hemostat
5.1.2.4 Thrombin-based topical hemostat
5.1.2.5 Combination topical hemostat
5.1.3 Tissue Sealants
5.1.3.1 Fibrin sealants
5.1.3.2 Protein-based sealants
5.1.4 Cyanoacrylate-based tissue adhesives
5.1.5 Adhesion prevention products
5.1.6 Y-o-Y Growth Analysis, By Product Type
5.1.7 Market Attractiveness Analysis, By Product Type
5.1.8 Market Share Analysis, By Product Type
5.2 Application
5.2.1 Wound Closure
5.2.2 Surgical Hemostats
5.2.3 Y-o-Y Growth Analysis, By Application
5.2.4 Market Attractiveness Analysis, By Application
5.2.5 Market Share Analysis, By Application
5.3 Distribution Channel
5.3.1 Direct Tenders
5.3.2 Retail
5.3.3 Y-o-Y Growth Analysis, By Distribution Channel
5.3.4 Market Attractiveness Analysis, By Distribution Channel
5.3.5 Market Share Analysis, By Distribution Channel
5.4 End User
5.4.1 Hospitals
5.4.2 Ambulatory Centers
5.4.3 Community Healthcare
5.4.4 Clinics
5.4.5 Y-o-Y Growth Analysis, By End User
5.4.6 Market Attractiveness Analysis, By End User
5.4.7 Market Share Analysis, By End User
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product Type
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product Type
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product Type
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Johnson & Johnson Services, Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 C. R. Bard, Inc.
8.3 Baxter
8.4 B. Braun Melsungen Ag
8.5 Pfizer Inc.
8.6 Vascular Solutions, Inc.
8.7 Gelita Medical Gmbh
8.8 Equimedical
8.9 Integra Lifesciences Holdings Corporation
8.10 Z-Medica, LLC
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Apr 2021
